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Backgrounds & Aims 
The gastrointestinal (GI) tract is the most common internal 
organ system affected in SSc. We and others have shown 
before that the SSc immunoglobulins (IgGs) cause selective 
blockade of muscarinic type-3 cholinergic (M3-R) in the GI tract. 
Presently, there is no effective treatment for SSc although 
numerous cytotoxic and immunomodulatory agents have been 
employed with limited success and are marred with serious side 
effects. Present studies investigated the reversibility of 
SScIgGs-caused M3-R blockade by the pooled Intravenous 
immunoglobulins (IVIG).  
Methods 
Effects of SScIgGs and IgGs from normal individuals (NIgGs) on 
M3-R activation by bethanechol (BeCh) were determined in 
human internal anal sphincter (IAS) smooth muscle cells 
(SMCs), before and after IVIG.  M3-R occupancy and binding by 
the SScIgG was determined via immunofluorescence (IF), 
Western blotting, and ELISA, respectively. Functional 
displacement of M3-R occupancy by the SScIgGs was 
determined employing different concentrations of the IgGs 
during the sustained phase of the BeCh-induced contraction of 
rat IAS smooth muscle strips. 
Results 
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Figure 1. (A) M3-R occupancy with SScIgG (vs. NIgG and IVIG) in the SMC membrane as 
determined by IFI/unit area. (B) Graph showing SScIgG binding to SMC membrane. 
(C.) Schematics of membrane Intensity calculation. 
Fig. 1 
Fig. 2 
Figure 2. (A) Immunocytochemical co-localization of different IgGs (a,b,c,d,e) (FITC-
conjugated; green) and M3-R (TR-conjugated; red). (B) Pearson’s coefficient shows significant 
colocalization of SScIgG and M3-R.  
Fig. 3 
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Figure 3. (A) SScIgG (and not NIgG and IVIG) in resemblance with darifenacin (M3-R 
selective inhibitor) causes significant and conc.-dependent decrease in the BeCh-induced 
sustained contraction of IAS (*; p < 0.05; n = 6). (B) Actual tracings of the above effects. 
Fig. 4 
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Figure 4. (A) ELISA binding studies for M3-R peptide and human IAS SMC membrane 
fraction (HISMF): Standard curves with M3-R and HISMF. (B) Data show M3-R antibody and 
SScIgG bind with HISMF in a conc.-dependent manner (*; p < 0.05; n = 6), and IVIG 
significantly decreases this binding. (C) Similar data were obtained when M3-R peptide (M3-
RL2) instead of HISMF was used. 
Fig. 5 
Figure 5. SScIgGs significantly  bind with M3-R 
(*; p < 0.05), in (HISMF).  IVIG reverses this 
binding (*; p < 0.05). 
Figure 6. Active IVIG (not inactivated) 
neutralizes (*; p < 0.05) the binding of SScIgG 
with M3-RL2 and the HISMF. 
1. IgGs from scleroderma patients (SScIgGs) inhibit muscarinic type-3 cholinergic (M3-R) activation, as 
shown by the data in human IAS smooth muscle cells and  rat smooth muscle strips. 
2. SScIgGs inhibit  M3-R occupation as shown by immunocytochemistry and Elisa-binding studies. 
3. Pooled intravenous globulin (IVIG) reverses the M3-R occupancy and activation primarily by 
neutralizing circulating the SScIgGs. 
Summary 
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Conclusions 
• IVIG abrogates SScIgGs-mediated block of M3-R by blocking the circulating SScIgGs. 
• This mechanism may be partly responsible for the restoration of M3-R-mediated cholinergic dysfunction 
in SSc-related GI manifestations. 
Proposed  Mechanism of Action of Pooled Human Immunoglobulin (IVIG) 
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